Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: GlobeNewswire
Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy moleculesANKET is first NK cell engager technology to engage NKp46, CD16, IL-2 variant and tumor antigen in a single tetra-specific moleculeToday’s preclinical data highlight robust anti-tumor efficacy across several in vivo tumor models and manageable safety profileInnate to feature the data in upcoming virtual IR R&D event on Wednesday, June 23 MARSEILLE, France, June 10, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKET™ (Antibody-based NK cell Engager Therapeutics) at the Federation of Clinical Immunology Societies (FOCIS) meeting. The presentation will take place at 7 pm CEST today. Specifically, Innate will share new data from its tetra-specific ANKET mo
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateBusiness Wire
- NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma) [Yahoo! Finance]Yahoo! Finance
- Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio [Yahoo! Finance]Yahoo! Finance
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 [Yahoo! Finance]Yahoo! Finance